Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
Crossref DOI link: https://doi.org/10.1038/leu.2017.330
Published Online: 2017-11-16
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pardanani, A
Gotlib, J
Roberts, A W
Wadleigh, M
Sirhan, S
Kawashima, J
Maltzman, J A
Shao, L
Gupta, V
Tefferi, A
Text and Data Mining valid from 2017-11-16
Article History
First Online: 16 November 2017
Competing interests
: The authors declare no conflict of interest.